Sugi Predict

Sugi Predict / Compounds / SCHEMBL10102396

SCHEMBL10102396

SCHEMBL10102396

COc1ccc(C2(c3ccc(N4CCOCC4)cc3)C=Cc3c4c(c5ccc(OC)cc5c3O2)-c2ccccc2C42CC(C)(C)CC(C)(C)C2)cc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.33
▸ TSHR P16473 3/20 0.33
▸ HSD17B10 Q99714 3/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ MAPK1 P28482 2/20 0.33
▸ POLB P06746 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ ADAM17 P78536 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ ATM Q13315 3/20 0.32
▸ PRKDC P78527 2/20 0.32
▸ STK10 O94804 1/20 0.31
▸ SLK Q9H2G2 1/20 0.31
▸ AKT1 P31749 1/20 0.31
▸ PIK3C3 Q8NEB9 2/20 0.31
▸ ALDH1A1 P00352 4/20 0.31
▸ KDM4E B2RXH2 3/20 0.31
▸ TP53 P04637 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ HTT P42858 3/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20369879 0.98 MAPT (0.34) MAPTTSHRHSD17B10KMT2AMAPK1
SCHEMBL676103 0.98 MAPT (0.34) MAPTTSHRHSD17B10KMT2AMAPK1
SCHEMBL12424707 0.95 MAPT (0.33) MAPTTSHRHSD17B10KMT2AMAPK1
SCHEMBL10106918 0.95 MAPT (0.34) MAPTTSHRHSD17B10KMT2AMAPK1
SCHEMBL13868746 0.95 RAB9A (0.33) MAPTKMT2AADAM17RAB9AATM
SCHEMBL10102281 0.94 MAPT (0.31) MAPTTSHRHSD17B10KMT2AALDH1A1
SCHEMBL13868646 0.93 PRKDC (0.36) MAPTKMT2ASMN1; SMN2ADAM17RAB9A
SCHEMBL13868676 0.92 PRKDC (0.37) MAPTTSHRHSD17B10KMT2AMAPK1
SCHEMBL10102279 0.92 MAPT (0.32) MAPTTSHRHSD17B10KMT2AALDH1A1
SCHEMBL9928170 0.91 KDM4E (0.33) TSHRHSD17B10KMT2AATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8308995-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-11-13 — — US disclosed
US-8308995-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-11-13 — — US disclosed
US-20120138876-A1 CHROMENE COMPOUND KASAI SOKO (JP) 2012-06-07 — — US disclosed
US-20120138876-A1 CHROMENE COMPOUND KASAI SOKO (JP) 2012-06-07 — — US disclosed
US-8147726-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-04-03 — — US disclosed
US-8147726-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-04-03 — — US disclosed
US-20110062396-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2011-03-17 — — US disclosed
US-20110062396-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2011-03-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120138876-A1 CHROMENE COMPOUND CHRM1, CBX8, CBX7 MAPT 3134/4885TSHR 354/4885HSD17B10 1470/4885
US-20110062396-A1 CHROMENE COMPOUND CDYL, NR0B1, NR1H2 MAPT 4740/4885TSHR 330/4885HSD17B10 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.